迈得医疗(688310.SH)披露2025年第三季度报告，公司前三季度实现营收2.25亿元，同比增长2.31%;归母 净利润884万元，同比增长15.82%;扣非净利润亏损128万元;基本每股收益0.05元。 ...

Core Points - The company held its fifth board meeting on October 27, 2025, where multiple resolutions were passed, including the approval of the Q3 2025 report and the postponement of fundraising projects [1][2][3] Group 1: Board Meeting Overview - The board meeting was legally valid with all seven directors present, as notified via email on October 22, 2025 [2] - The meeting was chaired by Chairman Lin Junhua, ensuring compliance with legal requirements [2] Group 2: Q3 2025 Report Approval - The board approved the Q3 2025 report, which has been disclosed on the Shanghai Stock Exchange website for investors to review detailed financial data and operational conditions [3] - The resolution received unanimous support with 7 votes in favor and no opposition or abstentions [3] Group 3: Fundraising Project Postponement - The board agreed to extend the timeline for the "Annual Production of 35 Medical Equipment Combination Intelligent Devices Expansion Project" from November 2025 to November 2026, effectively delaying the project by one year [4] - This project is a core capacity expansion initiative focused on the medical equipment sector, and the decision was also unanimously approved with 7 votes in favor [4] - Detailed reasons and impacts of the project delay have been disclosed in a separate announcement available on the Shanghai Stock Exchange website [4]

Group 1 - The core viewpoint of the article highlights the financial performance of Maide Medical for the third quarter of 2023, showing a modest growth in revenue and net profit [1] - For the first three quarters of 2025, the company's revenue is approximately 225 million yuan, representing a year-on-year increase of 2.31% [1] - The net profit attributable to shareholders of the listed company is about 8.84 million yuan, reflecting a year-on-year increase of 15.82% [1] - The basic earnings per share is reported at 0.05 yuan, with no change compared to the previous year [1] Group 2 - As of the report date, Maide Medical has a market capitalization of 3.5 billion yuan [2]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-042 迈得医疗工业设备股份有限公司 关于公司募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈得医疗工业设备股份有限公司（以下简称"公司"）于2025年10月27日召 开第五届董事会第五次会议、第五届监事会第五次会议，审议通过了《关于公司 募投项目延期的议案》，同意公司对"年产35台药械组合类智能装备扩建项目" 达到预定可使用状态的日期进行延期。保荐机构广发证券股份有限公司（以下简 称"保荐机构"）对该事项出具了明确的核查意见。该事项无需提交公司股东大 会审议。现将有关情况公告如下： 一、 募集资金基本情况 根据中国证券监督管理委员会《关于同意迈得医疗工业设备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2019 号），中国证券监督管理 委员会同意公司首次公开发行股票的注册申请。公司首次公开发行人民币普通股 （A 股）股票 2,090 万股，每股面值人民币 1.00 元，每股发行价格 24.79 元，募 集资金总额为人民 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-041 迈得医疗工业设备股份有限公司 第五届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第五届监事会第五次会 议（以下简称"本次会议"）于 2025 年 10 月 27 日以现场表决方式在公司会议室 召开。本次会议的通知已于 2025 年 10 月 22 日以电子邮件方式送达全体监事。 本次会议由监事会主席吴江平先生主持，应出席会议监事 3 人，实际出席会议监 事 3 人。本次会议的召开符合《中华人民共和国公司法》等法律、行政法规以及 《迈得医疗工业设备股份有限公司章程》的相关规定。 具体内容详见公司于同日披露在上海证券交易所网站（www.sse.com.cn）的 《迈得医疗工业设备股份有限公司关于公司募投项目延期的公告》（公告编号： 2025-042）。 二、监事会会议审议情况 经与会监事审议表决，通过了如下议案： 表决结果：同意：3 票；反对：0 票；弃权 ...

迈得医疗工业设备股份有限公司 证券代码：688310 证券简称：迈得医疗 公告编号：2025-040 (二)审议通过了《关于公司募投项目延期的议案》 第五届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第五届董事会第五次会 议（以下简称"本次会议"）于 2025 年 10 月 27 日以现场加通讯的方式在公司会 议室召开。本次会议的通知已于 2025 年 10 月 22 日以电子邮件方式送达全体董 事。本次会议由董事长林军华先生主持，应出席会议董事 7 人，实际出席会议董 事 7 人。本次会议的召开符合《中华人民共和国公司法》等法律、行政法规以及 《迈得医疗工业设备股份有限公司章程》的相关规定。 二、董事会会议审议情况 经与会董事审议表决，通过了如下议案： (一)审议通过了《关于公司 2025 年第三季度报告的议案》 具体内容详见公司于同日披露在上海证券交易所网站（www.sse.com.cn）的 《迈得医疗工业设备股份有限 ...

Financial Performance - The company's revenue for the third quarter reached ¥83,642,998, representing a year-on-year increase of 54.38%[3] - The total profit for the period was a loss of ¥2,427,622.54, while the profit for the year-to-date was ¥751,211.30, reflecting a decrease of 83.68% compared to the previous year[3] - The net profit attributable to shareholders was ¥2,791,600.17 for the quarter, with a year-to-date net profit of ¥8,836,659.11, showing an increase of 15.82%[3] - Total operating revenue for the first three quarters of 2025 reached ¥224,643,650.85, an increase of 2.5% compared to ¥219,574,032.71 in the same period of 2024[20] - The company reported a net loss of ¥5,462,086.29 for the first three quarters of 2025, compared to a net profit of ¥2,032,527.91 in the same period of 2024[21] - Operating profit turned negative at -¥999,815.58, a significant decline from a profit of ¥5,295,471.14 in the previous year[20] Assets and Liabilities - The company's total assets increased by 13.70% year-on-year, reaching ¥1,197,742,892.15[4] - The company's total assets increased to ¥1,197,742,892.15, up from ¥1,053,411,101.81 year-over-year[17] - Total liabilities rose to ¥357,600,902.10, compared to ¥207,957,231.30 in the previous year, indicating a substantial increase in financial obligations[17] - The equity attributable to shareholders decreased slightly to ¥805,700,841.25 from ¥810,050,019.65 year-over-year[17] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥126,246,149.55, an increase of 195.71% compared to the previous year[3] - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $404.46 million, an increase from $376.77 million in the same period of 2024, representing a growth of about 7.3%[23] - The net cash flow from operating activities significantly improved to $126.25 million in 2025, compared to $42.69 million in 2024, indicating a substantial increase of approximately 195.5%[23] - Total cash inflow from investment activities was $712.46 million in 2025, a significant rise from $107.08 million in 2024, marking an increase of about 564.5%[24] - Cash outflow for investments surged to $867.87 million in 2025, compared to $282.70 million in 2024, reflecting an increase of approximately 207.5%[24] - The net cash flow from investment activities was negative at -$155.41 million in 2025, slightly improved from -$175.62 million in 2024[24] - The net cash flow from financing activities was positive at $21.74 million in 2025, contrasting with a negative flow of -$59.49 million in 2024[24] Research and Development - Research and development expenses totaled ¥13,136,170.78 for the quarter, accounting for 15.71% of revenue, a decrease of 0.09 percentage points compared to the previous year[4] - Research and development expenses for the first three quarters were ¥31,113,408.83, up from ¥28,854,806.83 in the same period last year, reflecting a focus on innovation[20] Shareholder Information - The top shareholder, Lin Junhua, holds 47.15% of the shares, while the second-largest shareholder, Chen Wanshun, holds 14.89%[12] - The company has a total of 4,528 preferred shareholders at the end of the reporting period[11] - The company has not reported any changes in major shareholders or their participation in securities lending activities during the reporting period[13] Market and Competition - The company faced intensified competition in the domestic market for safety infusion equipment, impacting gross margins and overall profitability[8] - The increase in revenue was attributed to orderly production according to order cycles, with unrecognized revenue of ¥7,645.20 pending confirmation[8] Other Information - The company has not disclosed any new product developments or technological advancements in the current reporting period[14] - There are no significant changes in the company's operational strategies or market expansion plans mentioned in the report[14] - The company will not apply new accounting standards or interpretations starting from 2025[25]

广发证券股份有限公司 关于迈得医疗工业设备股份有限公司 募投项目延期的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为迈得 医疗工业设备股份有限公司（以下简称"迈得医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等法律法规的规定， 对迈得医疗募投项目延期的事项进行了审慎核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意迈得医疗工业设备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2019 号），中国证券监督管理委 员会同意公司首次公开发行股票的注册申请。公司首次公开发行人民币普通股 （A 股）股票 2,090 万股，每股面值人民币 1.00 元，每股发行价格 24.79 元，募 集资金总额为人民币 51,811.10 万元，扣除发行费用人民币 6,075.96 万元（不含 税）后，募集资金净额为人民币 45,735.14 万元。该募集资金已于 2019 年 1 ...

迈得医疗公告，第三季度营收为8364.3万元，同比增长54.38%；净利润为279.16万元。前三季度营收为 2.25亿元，同比增长2.31%；净利润为883.67万元，同比增长15.82%。 ...

Core Insights - The stock of Maide Medical (688310) closed at 20.9 yuan on October 24, 2025, with a 1.36% increase and a trading volume of 19,500 lots, amounting to a total transaction value of 40.54 million yuan [1] Financial Performance - For the first half of 2025, Maide Medical reported a main revenue of 141 million yuan, a year-on-year decrease of 14.75% - The net profit attributable to shareholders was 6.0451 million yuan, down 38.81% year-on-year - The non-recurring net profit was -2.5149 million yuan, a decline of 135.52% year-on-year - In Q2 2025, the company achieved a single-quarter main revenue of 101 million yuan, an increase of 10.58% year-on-year - The single-quarter net profit attributable to shareholders was 16.8424 million yuan, a significant increase of 2759.64% year-on-year - The single-quarter non-recurring net profit was 11.8767 million yuan, up 923.08% year-on-year [3] Market Position - Maide Medical's total market capitalization is 3.474 billion yuan, compared to the industry average of 7.749 billion yuan, ranking 188 out of 268 in the specialized equipment industry - The company's net assets stand at 828 million yuan, with an industry average of 2.253 billion yuan, ranking 200 out of 268 - The net profit of 6.0451 million yuan places the company at 193 out of 268 in the industry, with a price-to-earnings ratio of 287.34, significantly higher than the industry average of 51.37, ranking 191 out of 268 - The price-to-book ratio is 4.34, compared to the industry average of 3.97, ranking 169 out of 268 - The gross margin is 38.93%, above the industry average of 27.83%, ranking 43 out of 268 - The net margin is -1.29%, below the industry average of 0.66%, ranking 215 out of 268 - The return on equity (ROE) is 0.76%, compared to the industry average of 2.21%, ranking 190 out of 268 [3] Investment Sentiment - In the last 90 days, one institution has given a rating of "buy" for Maide Medical [4]